ORPHA:99970
Dedifferentiated liposarcoma
Also known as: DDLS
Publications
4,016
Trials
36
Interventional, condition-specific
Researchers
1,447
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Dedifferentiated liposarcoma (DDLS) is a high-grade subtype of liposarcoma (LS) that progresses from well-differentiated liposarcoma (WDLS), and most often occurs in the retroperitoneum. It is defined as a region of nonlipogenic sarcoma associated with WDLS. .
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0020563
- UMLS:C0205824
- NCIT:C3704
Additional Mondo synonyms (2)
DDLPS · dedifferentiated liposarcoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
4,016 matched papers (3,102 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
36 matched on ClinicalTrials.gov (11 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
4,016
4,016 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
4,016 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
3,102 in the last 10 years · low confidence
Phrase hits: 4,016 · MeSH hits: 0
Who's working on it?
1,447
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Ichikawa J8 papers · 2026
Department of Orthopaedic Surgery, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Japan.
Papers in Europe PMC - 02Kawasaki T8 papers · 2026
Department of Pathology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Papers in Europe PMC - 03Wako M8 papers · 2026
Department of Orthopaedic Surgery, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Japan.
Papers in Europe PMC - 04Wang Y8 papers · 2026
Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610213, China.
Papers in Europe PMC - 05Onohara K7 papers · 2025
Department of Radiology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Japan.
Papers in Europe PMC - 06Wang X6 papers · 2026
Department of Joint Surgery, The 940th Hospital of Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou, Gansu 730050, P.R. China.
Papers in Europe PMC - 07Li W5 papers · 2026
Department of Retroperitoneal Tumor and Anorectal Surgery, Peking University International Hospital Beijing 100044, China.
Papers in Europe PMC - 08Li Y5 papers · 2026
Department of Radiology, Peking University Third Hospital, Beijing, China.
Papers in Europe PMC - 09Liu J5 papers · 2026
Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Papers in Europe PMC - 10Ochiai S5 papers · 2025
Department of Orthopaedic Surgery, National Hospital Organization (NHO) Kofu National Hospital, Kofu, Japan.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
36
interventional trials for this specific condition
36 interventional trials matched this specific condition name; 11 currently recruiting in our sample. 98 trials are registered for liposarcoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
36 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 96.1th percentile).
low confidence · 96.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
36 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06498648·RECRUITING·Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
Conditions: Advanced Dedifferentiated Liposarcoma · Advanced Leiomyosarcoma · Advanced Soft Tissue Sarcoma · Metastatic Dedifferentiated Liposarcoma·Matched via name phrase
- NCT06389799·RECRUITING·A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)
Conditions: Dedifferentiated Liposarcoma·Matched via name phrase
- NCT05711615·RECRUITING·Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Conditions: Metastatic Dedifferentiated Liposarcoma · Metastatic Leiomyosarcoma · Metastatic Myxofibrosarcoma · Metastatic Sarcoma·Matched via name phrase
- NCT06422806·RECRUITING·Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Conditions: Metastatic Dedifferentiated Liposarcoma · Metastatic Undifferentiated Pleomorphic Sarcoma · Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 · Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8·Matched via name phrase
- NCT06025747·RECRUITING·A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas
Conditions: Retroperitoneal Sarcoma · Liposarcoma · Dedifferentiated Liposarcoma·Matched via name phrase
- NCT06843967·RECRUITING·A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Conditions: Well Differentiated Liposarcoma · Dedifferentiated Liposarcoma · Liposarcoma · Myxoid Liposarcoma·Matched via name phrase
- NCT06789172·RECRUITING·A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Conditions: Solid Tumours · Sarcoma · HNSCC · Non Small Cell Lung Cancer·Matched via name phrase
- NCT06526897·NOT YET RECRUITING·Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma
Conditions: Adult Pleomorphic Rhabdomyosarcoma · AJCC Grade 2 Sarcoma · AJCC Grade 3 Sarcoma · Alveolar Soft Part Sarcoma·Matched via name phrase
- NCT05607095·RECRUITING·A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
Conditions: Uveal Melanoma · Melanoma · Metastatic Uveal Melanoma · Metastatic Melanoma·Matched via name phrase
- NCT06694324·NOT YET RECRUITING·First-line Treatment of Advanced/unresectable DDLPS
Conditions: Dedifferentiated Liposarcoma · Soft Tissue Sarcoma (STS)·Matched via name phrase
- NCT06975293·RECRUITING·STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
Conditions: Solid Tumor · Sarcoma · Leiomyosarcoma · Dedifferentiated Liposarcoma·Matched via name phrase
Broader category: liposarcoma
98
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06957431·RECRUITING·Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Conditions: Advanced Leiomyosarcoma · Adipocytic Sarcoma · Advanced Liposarcoma·Matched via name phrase
- NCT07224568·NOT YET RECRUITING·Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors
Conditions: Solid Tumor (Excluding CNS) · Hepatocellular Carcinoma · Liver Cell Carcinoma · Liposarcoma·Matched via name phrase
- NCT05492682·RECRUITING·START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Conditions: Melanoma (Skin) · Triple-Negative Breast Cancer · Non-Small Cell Lung Cancer · Synovial Sarcoma·Matched via name phrase
- NCT04785196·RECRUITING·APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Conditions: Liposarcoma · Advanced Solid Tumor·Matched via name phrase
- NCT07686367·NOT YET RECRUITING·Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers
Conditions: Metastatic Myxoid Liposarcoma · Metastatic Synovial Sarcoma · Unresectable Myxoid Liposarcoma · Unresectable Synovial Sarcoma·Matched via name phrase
- NCT07169344·RECRUITING·Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma
Conditions: Soft Tissue Sarcoma (Excluding GIST) · Soft Tissue Sarcoma Adult · Soft Tissue Sarcoma of the Trunk and Extremities · Synovial Sarcomas·Matched via name phrase
- NCT06849986·RECRUITING·IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
Conditions: Soft Tissue Sarcomas · Angiosarcoma · Fibrosarcoma · Leiomyosarcoma·Matched via name phrase
- NCT04224064·RECRUITING·Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas
Conditions: Liposarcoma · Atypical Lipomatous Tumor·Matched via name phrase
- NCT07173972·RECRUITING·Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.
Conditions: Soft Tissue Sarcoma (STS) · Soft Tissue Sarcoma Adult · Soft Tissue Sarcoma of the Trunk and Extremities · Synovial Sarcomas·Matched via name phrase
- NCT06239272·RECRUITING·NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Conditions: Adipocytic Neoplasm · Liposarcoma · Atypical Fibroxanthoma · Angiomatoid Fibrous Histiocytoma·Matched via name phrase
- NCT07261657·RECRUITING·N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy
Conditions: Myxoid Liposarcoma · Round Cell Liposarcoma · Synovial Sarcoma·Matched via name phrase
- NCT06748872·NOT YET RECRUITING·EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma
Conditions: Epithelial Ovarian Cancer · Gastro-esophageal Junction Cancer · Soft Tissue Sarcoma (STS) · Myxoid Liposarcoma·Matched via name phrase
- NCT06198296·RECRUITING·Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Conditions: Hepatoblastoma · Hepatocellular Carcinoma · Wilms Tumor · Malignant Rhabdoid Tumor·Matched via name phrase
- NCT04715191·RECRUITING·Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Conditions: Liver Cancer · Rhabdomyosarcoma · Malignant Rhabdoid Tumor · Liposarcoma·Matched via name phrase
- NCT07148050·RECRUITING·Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Conditions: Solid Tumor (Excluding CNS) · Liver Cell Carcinoma · Malignant Rhabdoid Tumor · Yolk Sac Tumor·Matched via name phrase
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Dedifferentiated liposarcoma" OR "DDLPS"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Dedifferentiated liposarcoma" OR "DDLPS"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 36 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"liposarcoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: DDLS
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (4016) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T06:48:28.785Z
